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Background. Acute renal failure (ARF) occurs commonly in
the intensive care unit (ICU), but predicting which patients will
develop ARF is difficult. We set out to determine which risk
factors would predict the development of ARF in critically ill
patients who are admitted to the ICU without ARF.
Methods. From August 2002 to April 2003, we enrolled
medical-surgical ICU admissions into a cohort using a sampling
tool based on their risk factor (RF) profile. The risk factors
we identified were separated into 3 categories: chronic major,
chronic minor, and acute RFs. Combinations of these RFs were
used to create a sampling tool and identify patients to enroll
into our cohort. Patients with end-stage renal disease and ARF
upon admission to the ICU were excluded.
Results. We enrolled 194 patients over a 14-month period.
The mean age of the cohort was 64.6 ± 14.7 years. The per-
centage of Caucasians, African Americans, and Hispanics was
40.7%, 50.5%, and 3.6%, respectively. In a univariate analysis
of the entire cohort, increasing APACHE II quartile, increased
A-a gradient, presence of systemic inflammatory response syn-
drome (SIRS), decreased levels of serum albumin, and presence
of active cancer predicted ARF. In a multiple logistic regression
analysis, decreased serum albumin (high levels of serum albu-
min were protective), increased A-a gradient, and cancer were
associated with development of ARF (OR 2.17, 1.04, and 2.86,
respectively).
Conclusion. Decreased levels of serum albumin concentra-
tion, increased A-a gradient, and presence of active cancer pre-
dict which patients who are admitted to the ICU will develop
ARF.
Critically ill patients are at high risk for developing
acute renal failure (ARF), which is associated with in-
creased mortality [1]. Those critically ill patients with
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ARF who require renal replacement therapy (RRT) have
a mortality of 50% to 80% [1–3]. Despite the many ad-
vances in research techniques over the past 20 years, and
the introduction of genomic and proteonomic techniques,
fundamental changes in the outcome of patients who de-
velop ARF have not occurred [4]. The limited progress
is related to many factors, including: (1) lack of a consen-
sus definition for ARF; (2) lack of diagnostic tests that
indicate the onset of ARF and renal injury; and (3) the
absence of therapy for ARF aside from renal replacement
therapy [5].
The considerable success of acute intervention in my-
ocardial infarction is predicated on rapid, early recogni-
tion that allows swift therapeutic intervention. Similarly,
it is likely that therapeutic agents will need to be initiated
close to the time of renal insult in order for significant
clinical benefit to be realized. Animal models of ARF us-
ing ischemic, toxic, and septic models have all suggested
multiple therapeutic agents that appear to attenuate renal
injury if administered before insult or shortly thereafter
[6–12]. However, no randomized controlled studies in hu-
mans to date have shown benefit in treating established
ARF [5, 13, 14].
The vast majority of ARF studies in humans (includ-
ing the Anaritide and the Insulin Growth Factor-1 clinical
trials) used increases in serum creatinine concentration
(Scr) as the mainstay of determining which patients have
ARF [13, 14]. Scr has significant limitations as a marker of
renal injury. Scr is dissolved in extracellular water; when
patients are volume expanded (e.g., resuscitation in pa-
tients with sepsis) decreases in glomerular filtration rate
(GFR) are often not reflected by a commensurate in-
crease in Scr. Because of these limitations, using increases
in Scr as a marker of ARF prevents intervention at the on-
set of renal injury. In current clinical practice, the recog-
nition of ARF often occurs many hours to days after the
initial insult. An ideal kidney injury marker would have
similar properties as the cardiac injury marker troponin.
This injury marker would be characterized by specificity
for kidney injury, and would become detectable in the
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blood or urine immediately after the onset of significant
kidney injury. In order to delineate a biomarker that pos-
sesses the key characteristics mentioned above, samples
must be acquired before the current clinical recognition
of ARF occurs. Currently, ARF occurs in approximately
7.2% of hospital admissions [15]. If blood and urine were
drawn daily (pre-kidney injury) in patients admitted to a
hospital, only 7.2% of those samples would be relevant
for kidney injury biomarker assessment. If, however, the
selected cohort had a higher incidence of ARF, identified
by predictive modeling, the yield for daily collection of
blood and urine would be much higher. With this goal
in mind, we set out to develop a risk factor model that
could be used to identify the group of critically ill patients
at highest risk for developing ARF.
Individual clinical variables that predict ARF have
been described in subset groups of critically ill patients
[6, 16]. The diversity of patients who become critically
ill has created a large number of important predictors
of ARF. These include but are not limited to: chronic
kidney disease (CKD), pH <7.30, elevated severity of ill-
ness score (APACHE II, III or SAPS II), advanced age,
history of congestive heart failure, elevated bilirubin, cir-
rhosis, cancer, mechanical ventilation, hypotension, olig-
uria, valvular surgery, use of intra-aortic balloon pump,
increased body mass index, history of hypertension, and
atherosclerotic cardiovascular disease (ASCVD) [1, 2, 4,
6, 16–22]. These studies were conducted in a retrospec-
tive fashion searching for the clinical and demographic
predictors of ARF. We would like to be able to predict,
on admission to the ICU, which patients during their stay
in the ICU will experience ARF.
METHODS
According to the existing literature, some patients are
at high risk for and others are at lower risk for devel-
oping ARF. We sampled our ICU admission population
for patients that were at low and high risk for developing
ARF. By using a screening tool to enter low- and high-risk
patients into our cohort we hoped to eliminate patients
who were at very low risk and those patients who are
already in ARF because these types of patients are less
informative.
We created a sampling tool based on the premise that
comorbidities alone would not predict those patients at
high risk for ARF. We speculated that the combination
of well-known comorbidities associated with ARF [e.g.,
diabetes mellitus (DM), CKD, advanced age, and AS-
CVD] and acute risk factors (e.g., volume depletion,
nephrotoxin exposure, sepsis) would prospectively pre-
dict those patients at high risk for ARF more frequently
than either type of risk factor alone. Chronic and acute
risk factors were determined by reviewing the ARF lit-
erature and by identifying comorbidities we felt to be
associated with ARF in our institution. The chronic risk
factors we identified were: DM, CKD, ASCVD, advanced
age (age >70 years), a history of hypertension (HTN),
elevated serum bilirubin, cancer, morbid obesity (BMI
>30 kg/m2), HIV infection, congestive heart failure, and
history of cerebral vascular accident (CVA) [2, 4, 18, 21–
23]. The acute risk factors were volume depletion, expo-
sure to nephrotoxin, high-risk surgery, hypotension, and
presence of systemic inflammatory response syndrome
(SIRS) or sepsis.
We further classified chronic risk factors into 2 groups:
major and minor. The major risk factors were: history
or presence of DM, CKD, ASCVD, and age >70 years.
The remaining chronic risk factors were designated minor
risk factors. The definition of each risk factor is described
in Table 1. The major, minor, and acute risk factors are
summarized in Table 2. We decided to use a stratified
risk factor system to determine our high-risk and low-
risk groups. The high-risk group was defined as patients
with 1 major risk factor plus 1 acute risk factor, 2 minor
risk factors plus 1 acute risk factor, or 2 acute risk factors.
Patients who were admitted to the ICU with preexist-
ing ARF [defined by a rising Scr (increase of 50% from
baseline) or a urine output less than 0.5 mL/kg/hr for the
12–48 hours before enrollment] were excluded. The low-
risk group was defined as patients with 1 major or 1 acute
risk factor, but not both. The criteria for both groups are
shown in Table 3.
This study was conducted from August 2002 to April
2003 in the hospital ICU. The George Washington Uni-
versity Hospital ICU is a 48-bed combined medical-
surgical ICU that admits all critically ill adults, except
those with major thermal injuries. A waiver of informed
consent was obtained from the Institutional Review
Board (IRB) because the study involved chart review
only. In addition, because the study spanned the initia-
tion of the HIPAA law, we obtained a HIPAA waiver
from the George Washington University Committee on
Human Research and the privacy officer of the hospital.
All patients in the study were enrolled within 36 hours
of admission to the ICU. Each day, all new admissions
were evaluated for entry into the high-risk group. Each
day admissions were evaluated in the same order. Once
a patient was identified, he or she was enrolled in the
study. Patients were enrolled as pairs. After the first pa-
tient was identified, a patient for the low-risk group was
also identified and enrolled. If a low-risk patient could
not be identified, a high-risk patient was not enrolled in
the study on that day. On any given day, once a pair of
patients were identified and enrolled, any other newly
admitted patients that met high-risk criteria could also
be enrolled on that day. Once a subject was enrolled, de-
mographic data, clinical data, and relevant past medical
history were obtained, and these data were used to cal-
culate an admission APACHE II score. A-a gradient was
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Table 1. Definitions of risk factors
Risk factor Definition
Chronic kidney disease (CKD) Creatinine >2.0 mg/dL in men, or >1.8 mg/dL in women
Advanced age >70 years
Atherosclerotic cardiovascular disease (ASCVD) History of angina pectoris, CAD, myocardial infarction, or peripheral vascular disease
Diabetes mellitus (DM) History of diabetes mellitus
Congestive heart failure (CHF) New York Heart Association Grade III or IV heart failure
History of hypertension (HTN) History of hypertension or patients receiving chronic hypertensive medications
Hyperbilirubinemia Serum total bilirubin >2.0 mg/dL
Morbid obesity BMI >30.0 kg/m2
Cancer Active cancer (patients not in remission and without surgical cure)
HIV infection History of testing positive for HIV antibodies
History of cerebrovascular accident (CVA) History of any type of CVA
SIRS/Sepsis SIRS: 2 of these findings: respiratory rate >20/min, pulse >90/min, temperature >38◦C
or <36◦C, white blood cell count >12,000/mL or <4000/mL; or sepsis: SIRS with
suspected or proven microbial origin
Hypotension MAP <70 mm Hg or any vasopressor except dopamine dosed at less than
5.0 lg/kg/minute
Volume depletion Central venous pressure (CVP) <6 cm of H2O or pulmonary capillary wedge pressure
(PCWP) <8 cm of H2O
High-risk surgery Cardiac surgery (valvular or coronary artery bypass grafting), aortic surgery,
hepatobiliary surgery (excluding cholecystectomy)
Nephrotoxin exposure Amphotericin B, aminoglycosides, nonsteroidal anti-inflammatory drugs (NSAIDs),
excluding aspirin, radiocontrast given within 24 hours
calculated using the sea level standard formula [(713 ×
(FIO2)—(PCO2/0.8)—PaO2]. In addition, all major, mi-
nor, and acute risk factors present at time of enrollment
were recorded. Subjects were followed throughout their
ICU stay; the primary end point of the study was the de-
velopment of ARF in the ICU. The secondary end point
was the need for RRT. Because there was no validated
consensus clinical definition of ARF at the time this study
was initiated, we used the definition of ARF outlined
here: >75% increase in serum creatinine if baseline crea-
tinine ≤2.0 mg/dL, or >50% increase in serum creatinine
if baseline creatinine >2.0 mg/dL (a serum creatinine of
1.8 mg/dL was used if the patient was female).
Statistics
Proportions of patients with certain characteristics
were compared using the chi-square test. We assessed
the distribution of variables. Variables with normal dis-
tribution were compared using two-tailed unpaired t tests,
while data that did not conform to a normal distribution
were compared using the Mann-Whitney rank sum test.
Major risk factors, minor risk factors, acute risk factors,
APACHE II score, and other clinically applicable vari-
ables were entered into a univariate logistic regression
with ARF as the dependent variable. Once univariate
predictors of ARF were identified, these variables were
then entered into a multivariate regression model with
ARF as the dependent variable. Age was placed into the
equations as a continuous variable, and as age decile. Sim-
ilarly, APACHE II score was entered into equations as a
continuous variable and as APACHE II quartile. Unless
otherwise specified, all means are reported as ± SD. All
Table 2. Summary of the chronic and acute risk factors
Chronic major risk factors Advanced age, DM, ASCVD, or CKD
Chronic minor HTN, morbid obesity, elevated bilirubin,
risk factors CVA, HIV, or cancer
Acute risk factors Hypovolemia, hypotension, high-risk
surgery, nephrotoxin exposure,
SIRS, or sepsis
Table 3. Definition of groups
High-risk group Low-risk group
1 acute risk factor + 1 major 1 major risk factor or 1 acute
risk factor OR risk factor (BUT NOT BOTH)
1 acute risk factor + 2 minor Multiple major risk factors
risk factors OR without acute risk factors
2 acute risk factors Multiple major and minor risk
factors without acute risk factors
statistics were performed with SPSS 11.0 (SPSS, Chicago,
IL, USA).
RESULTS
We enrolled a total of 194 patients over a 14-month
period. The mean age of the cohort was 64.6 ± 14.7 years.
The percentage of Caucasians, African Americans, and
Hispanics was 40.7%, 50.5%, and 3.6%, respectively. The
percentage of men was 53.6%. The prevalence of dia-
betes, ASCVD, and CKD was 36.6%, 30.4%, and 18%,
respectively. The mean body mass index (BMI) was 28.3±
10.4 kg/m2 and the mean serum albumin was 3.00 ±
0.79 g/dL. The mean APACHE II score was 12.5 ± 5.6.
The incidence of ARF based on our definition was 18.0%
(35 cases). Of the 35 patients that developed ARF, 13
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Table 4. Demographic characteristics of the patients
Variable ALL HRG LRG P value
Age years 64.6 + 14.7 66.4 ± 14.6 62.8 ± 15.7 0.12
Race (AA) 50.5% 56.7% 40.8% 0.24
Gender male 53.6% 60.3% 57.9% NS
APACHE II 12.5 + 5.6 13.5 ± 5.5 11.0 ± 6.1 <0.001a
APACHE II range 2–35 3–31 2–35
Incidence of ARF 18.0% 27.1% 3.9% 0.001a
Need for RRT 6.7% 10.2% 1.3% 0.025a
Abbreviations are: HRG, high-risk group; LRG, low-risk group; ARF, acute
renal failure, RRT, renal replacement therapy.
a P ≤ 0.05.
Table 5. Univariate predictors of ARF
OR 95% CI P value
Age decile 0.93 0.74–1.18 0.57
Chronic kidney disease 1.77 0.74–4.2 0.20
Diabetes mellitus 0.88 0.41–1.91 0.75
ASCVD 0.90 0.40–2.01 0.79
Hypertension 0.80 0.37–1.71 0.56
Cancer 3.75 1.68–8.4 0.001a
Morbid obesity 2.1 0.79–5.50 0.14
Congestive heart failure 1.85 0.74–4.58 0.19
Cerebrovascular accident 0.001 0.00–inf 0.96
Elevated serum bilirubin 3.6 0.78–17.0 0.10
SIRS 3.11 1.46–6.65 0.003a
High-risk surgery 1.51 0.68–3.37 0.31
Nephrotoxic exposure 0.001 0.00–inf 0.96
Hypotension 0.85 0.35–2.12 0.73
pH 0.18 0.005–6.4 0.35
Serum albumin 0.40 0.24–0.69 <0.001a
A-a gradient 1.044 1.015–1.074 0.003a
FIO2 1.01 0.99–1.030 0.07
APACHE II quartile 1.57 1.11–2.24 0.012a
a P value ≤ 0.05.
(37.1%) required RRT. None of the patients in our co-
hort who developed ARF died before requiring RRT.
One hundred and eighteen patients were enrolled in
the high-risk group (HRG), and 76 were in the low-risk
group (LRG). The demographic characteristics of the
2 groups were well matched (Table 4). The mean age
of the HRG and the LRG was 66.4 ± 14.6 and 62.8 ±
15.7 years, respectively (P = 0.12). There were 67 (56.7%)
African Americans in the HRG and 31 (40.8%) African
Americans in the LRG. The percentage of men in the
HRG and the LRG was 60.3% and 57.9%, respectively
(P = NS). The mean APACHE II score for the HRG
was 13.5 ± 5.5 while the mean APACHE II score for the
LRG was 11.0 ± 6.1 (P < 0.001). The incidence of ARF
in the HRG was 27.1% and 3.9% in the LRG (P = 0.001)
(Table 4); 10.2% of patients in the HRG and 1.3% of the
LRG patients required RRT (P = 0.025).
Clinical and demographic variables were assessed as
univariate predictors of ARF. A complete list of the
univariate relative risks and confidence intervals are
provided in Table 5. Age (years), age decile, presence
of diabetes, ASCVD, CKD, HTN, BMI, history of CVA,
serum bilirubin, history of CHF, presence of hypotension,
high-risk surgery, presence of nephrotoxin, and pH did
Table 6. Biochemical + preexisting condition models
Biochemical predictors RR Confidence Intervals P value
Serum albumin 0.45 0.24–0.85 0.013
A-a gradient 1.040 1.010–1.071 0.009
Preexisting condition
predictors RR Confidence Intervals P value
SIRS 2.81 1.28–6.14 0.01
Active cancer 3.38 1.48–7.73 0.004
Table 7. Multivariate analysis
RR Confidence Intervals P value
SIRS 1.224 0.45–3.33 0.69
Active cancer 2.814 1.01–7.85 0.048
Serum albumin 0.479 0.25–0.92 0.027
A-a gradient 1.039 1.01–1.07 0.015
Table 8. Multivariate analysis
RR Confidence Intervals P value
Active cancer 2.86 1.03–7.97 0.044
Serum albumin 0.46 0.25–0.86 0.016
A-a gradient 1.04 1.01–1.07 0.013
not predict the development of ARF. Presence of SIRS
and history of cancer predicted ARF, with a relative risk
of 3.11 (95% CI 1.46–6.65, P = 0.003) and 3.8 (95% CI
1.68–8.38, P = 0.001), respectively. For each 10 mm Hg in-
crease in A-a gradient there was a 4.4% increased relative
risk of developing ARF (RR 1.044, 95% CI 1.015–1.074,
P = 0.003). Increased serum albumin concentration was
associated with a relative risk of 0.4 of developing ARF
(95% CI 0.24–0.69, P < 0.001). In addition, APACHE II
quartile predicted the development of ARF with a rela-
tive risk of 1.6 (95% CI 1.1–2.24, P = 0.012).
Multivariate regression models built from the univari-
ate predictors of ARF are summarized in Tables 6, 7, and
8. We developed 4 multivariate models based on the 5
univariate parameters that predicted ARF, a biochemi-
cal model including serum albumin and A-a gradient, and
a preexisting condition model including history of cancer
and presence of SIRS (Table 6). When APACHE II quar-
tile was added to either of the biochemical or preexisting
condition models, APACHE II quartile did not predict
ARF (data not shown). In Table 7, biochemical predictors
and preexisting conditions are combined into a multivari-
ate model. In this model, history of cancer, serum albu-
min, and A-a gradient still predict ARF, whereas presence
of SIRS does not predict ARF. In Table 8, the 3 remaining
predictors of ARF (presence of serum albumin, history
of cancer, and A-a gradient) are entered into a model,
and all 3 of these variables predict the development of
ARF.
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DISCUSSION
In this pilot study of medical and surgical critically ill
patients we have been able to identify predictors of ARF.
In our pilot study, low serum albumin, increased A-a gra-
dient, and history of cancer were predictors of ARF upon
admission to the ICU. In addition, we found that combi-
nations of known risk factors were associated with a more
precise detection of ARF compared to solitary risk fac-
tors. If these predictors of ARF can be used to create
a predictive model two major advances might be real-
ized. One, modeling would allow efficient collection of
serum and urine specimens for biomarker analysis. Two,
given the poor tests in current use for diagnosis of ARF, a
preventive therapeutic trial could use modeling to target
patients at high risk for developing ARF. Instead of wait-
ing for ARF to develop, patients who are determined
to be at high risk for ARF could start to receive pre-
ventive/therapeutic agents upon ICU admission based
on their ARF risk profile. For example, if the general
ICU incidence of ARF were 10%, and a preventive drug
(e.g., N-acetyl cysteine) were given to all ICU patients
upon admission, for every 10 patients, 9 would be unnec-
essarily exposed to the intervention, while only 1 patient
would potentially gain benefit. If this type of model can
be enriched to 35% to 40% yield, the number of patients
needed to treat at highest risk for ARF would decrease.
Decreased levels of serum albumin have been shown
to be a predictor of mortality in patients with end-stage
kidney disease and in patients with ARF [24–27]. Corit-
sidis et al have successfully used a “bedside formula,”
which utilizes the serum albumin to predict which pa-
tients will develop ARF [28]. In their model, the “bedside
formula” predicted ARF better than APACHE scoring.
In an historic cohort, Ward showed that low serum albu-
min predicted which patients with rhabdomyolysis would
develop ARF [29]. In patients who are critically ill, de-
creased levels of serum albumin have often been ascribed
to poor nutritional status. However, serum albumin can
also fall significantly in response to inflammation and cap-
illary leak [30]. In our cohort of patients, it is impossible to
determine if the contribution of serum albumin to the de-
velopment of ARF is more related to nutritional status or
with degrees of inflammation. Increased serum concen-
trations of proinflammatory markers have been shown
to predict death in a variety of patient populations, and
poor nutritional status has long been known to be as-
sociated with increased mortality [31–33]. Malnutrition,
as measured by the subjective global nutritional assess-
ment (SGA), is associated with a poor clinical outcome
in patients with ARF [34]. Serum albumin is a part of the
SGA, but it is only one part of the biochemical compo-
nent of the SGA. If decreased levels of serum albumin
are validated in large cohorts of critically ill patients as a
predictor of ARF, the additional assessment of other nu-
tritional and inflammatory parameters (e.g., prealbumin,
C-reactive protein, serum concentration of proinflamma-
tory cytokines, etc.) would be useful in discriminating
why serum albumin predicts ARF. In our cohort, SIRS
predicted ARF as a univariate parameter, but did not
predict ARF in the multivariate analysis. Because serum
albumin concentrations often fall in the face of inflam-
mation, it is likely that in our cohort SIRS and decreased
serum albumin are colinear.
We also demonstrated that increased A-a gradient was
predictive of ARF. In a mixed med-surgical population
of critically ill patients, de Mendonca et al demonstrated
that respiratory failure was a predictor of the develop-
ment of ARF as measured by renal sequential organ fail-
ure assessment [2]. In our study, we did not specifically
code for respiratory failure because the decision about
when to intubate a patient can be quite subjective (e.g.,
airway protection, change in mental status, respiratory
distress, etc.).
The presence of active cancer was a strong determinant
of ARF in our cohort. Patients who have active cancer are
often exposed to a variety of clinical conditions known to
cause ARF. Patients receiving chemotherapy are often
treated with nephrotoxic chemotherapeutic agents [35,
36]. Cancer patients are also at risk for tumor lysis syn-
drome, volume depletion, direct toxicity from the neo-
plastic disease (e.g., multiple myeloma), and obstructive
renal disease due to mass occupying lesions [37–39]. In
addition, renal tubular cell recovery has been shown to
be impaired in animals that have received bone marrow
suppression [40, 41]. When patients become critically ill,
they are at a disadvantage due to their cancer burden
and concomitant immunosuppression. This background,
in combination with the multiple types of renal injury that
may have preceded or are concurrent with critical illness,
makes cancer patients particularly vulnerable to the de-
velopment of ARF [42]. In large cohorts of critically ill
patients, active cancer may be an underappreciated risk
factor.
Other investigators have assessed which risk factors
are associated with the development of ARF in subset
groups of critically ill patients (postcardiac surgery pa-
tients, trauma patients, and patients with sepsis) [16, 21,
24, 43, 44]. However, there is only one study of which
we are aware that evaluated critically ill patients taken
as a whole. De Mendonca et al evaluated a cohort of
1411 critically ill patients and used their renal sequential
organ failure assessment (SOFA) to evaluate the devel-
opment of ARF [2]. Patients who achieved a renal SOFA
score of 3 (serum creatinine >3.0 mg/dL or urine output
<500 mL/day) were considered to have developed ARF.
The most important risk factors for the development of
ARF present on admission were acute circulatory or res-
piratory failure, age greater than 65 years, presence of
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infection, past history of chronic heart failure (CHF),
lymphoma, leukemia, or cirrhosis. The population de
Mendonca et al [2] studied is the most similar to our pop-
ulation of critically ill patients. As in their study, we iden-
tified cancer and acute respiratory disease as significant
risk factors for the development of ARF. We speculate
that active cancer and respiratory disease will remain im-
portant predictors of ARF in future validated prediction
models of ARF.
Unlike de Mendonca’s study [2], we excluded patients
who were admitted to the ICU already suffering from
ARF. There are limited epidemiologic data available
comparing patients who develop ARF after ICU admis-
sion versus those patients who have ARF on admission
to the ICU. Guerin et al found patients who arrived in the
ICU with ARF had a lower mortality (61%) than patients
who develop ARF later in their ICU stay (71–81%) [45].
Further evaluation of these subgroups is warranted.
Our study has several limitations that may limit the
generalizability of our high-risk profile. First, the sam-
ple size of our population was relatively small. Second,
we chose a high-risk group and a low-risk group in or-
der to generate our cohort, but all of the admissions to
the ICU were not captured. In order to know how well
the high-risk group model performs, all ICU admissions
should be captured in order to determine the sensitivity,
specificity, negative, and positive predictive value of this
“test.” Third, the etiology of ARF was not determined.
Fourth, our definition of ARF was arbitrary. Currently,
there is no validated consensus definition for ARF, and
we anxiously await the validation of the RIFLE criteria
(Acute Dialysis Quality Initiative, www.adqi.net).
CONCLUSION
Risk factor profiling is a useful technique in identify-
ing those critically ill patients at high risk for developing
ARF. Risk factor profiling may be an important element
in the design of preventive clinical trials in patients at risk
for developing ARF. Risk factor profiling is not a surro-
gate marker of severity of critical illness. Decreased levels
of serum albumin, elevated A-a gradient, and active can-
cer appear to be strong determinants of the development
of ARF in patients who are critically ill. We are currently
conducting a prospective observational study of all ICU
admissions in order to validate these predictors of ARF.
We plan to develop a model that can accurately predict
which critically ill patients are at highest risk for devel-
oping ARF.
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